Drug Trial Radar · NCT04108208
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
Last checked: Nov 20, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
75
Actual
Start
Dec 17, 2019
Primary completion
Jun 1, 2023
Study completion Jun 5, 2026
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Sep 30, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the improvement in time to prostate specific antigen (PSA) progression (TTPP, as defined by Prostate Cancer Working Group 2 \[PCWG2\]) of apalutamide versus placebo in Chinese participants with high-risk non-metastatic castration resistant prostate cancer (NM-CRPC).
Conditions
- Prostatic Neoplasms
Interventions
ApalutamideDrug
Apalutamide 240 mg (4\*60 mg tablets) will be administrated orally once daily.
PlaceboDrug
Matching placebo will be administered orally.
Androgen-deprivation Therapy (ADT)Drug
Participants will continue to receive ADT with gonadotrophin-releasing hormone agonists (GnRHa) who have not been surgically castrated.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Prostate Specific Antigen (PSA) Progression (TTPP) Based on Prostate Cancer Working Group 2 (PCWG2) CriteriaTime frame: From randomization until first documented PSA progression (up to 3 years 3 months)
Locations
27 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
Peking University First Hospital
Beijing, China
Peking University People's Hospital
Beijing, China
Beijing Friendship Hospital
Beijing, China
Peking University Third Hospital
Beijing, China
Beijing Hospital
Beijing, China
Hunan Cancer hospital
Changsha, China
Sichuan Provincial Peoples Hospital
Chengdu, China
Chongqing University Cancer Hospital
Chongqing, China
Fujian Medical University Union Hospital
Fuzhou, China
Sun Yat-Sen Memorial Hospital Sun Yat-sen University
Guangzhou, China
Guangzhou First Municipal People's Hospital
Guangzhou, China
Zhejiang Provincial People's Hospital
Hangzhou, China
The First Affiliated Hospital Zhejiang University College of Medicine
Hangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
Nanjing Drum Tower Hospital
Nanjing, China
The First Affiliated Hospital of Ningbo University
Ningbo, China
Cancer Hospital, FuDan University
Shanghai, China
Shanghai Zhongshan Hospital
Shanghai, China
Huashan Hospital Fudan University
Shanghai, China
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China
The Fifth People's Hospital of Shanghai, Fudan University
Shanghai, China
Huadong Hospital Affiliated to Fudan University
Shanghai, China
First Affiliated Hospital SooChow University
Suzhou, China
TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology
Wuhan, China
Wuxi People s Hospital
Wuxi, China
The First Affiliated Hospital of Xian Jiaotong University
Xi'an, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.